View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
April 7, 2016

Deals this week: NantBioscience and Nantkwest, Cutis Pharma, Sorrento Therapeutics

NantBioscience and Nantkwest have entered a cooperative research and development agreement (CRADA) with National Cancer Institute (NCI) and National Institute of Health (NIH) to develop cancer therapies.

National Institute of Health

NantBioscience and Nantkwest have entered a cooperative research and development agreement (CRADA) with National Cancer Institute (NCI) and National Institute of Health (NIH) to develop cancer therapies.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The agreement enables to further develop recombinant NK cells and monoclonal antibodies as monotherapies and combination cancer immunotherapies.

Cutis Pharma will supply and jointly develop active pharmaceutical ingredients (API) under an agreement signed with Dr Reddy’s Laboratories.

Cutis believes the pact will help advance some of its products from research and development (R&D) phase to commercialisation, apart from helping it to expedite the new drug application (NDA) filing process and gain FDA approval of its drug candidates RM-02, RM-03 and RM-06 faster.

Sorrento Therapeutics has announced it is to to raise approximately $150m, by selling common stock at a price of $5.55 per share, through placement of more than 27 million of its shares and warrants. Being led by Ally Bridge Group, the offering is expected to be completed by the end of May 2016.

Proceeds are planned to be used partly to develop the company’s product pipeline and partly for meeting general corporate expenses. The placement will be subscribed to by Yuhan Corporation and institutional investors.

Yunnan Baiyao Group is offering bonds to the public in order to meet its additional capital requirements. Due in 2012, the gross value of these bonds is worth $138.5m.

Entasis Therapeutics has raised $50m to advance its clinical and pre-clinical anti-infective product pipeline.

Led by Clarus Venture, the series B financing round also included Frazier Helathcare partners, Novo A/S and Eventide Asset Management.


Image: NantBioscience and Nantkwest have entered a cooperative research and development agreement (CRADA) with National Institute of Health (NIH). Photo: courtesy: NIH.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena